Last update 24 Mar 2025

Bevacizumab biosimilar(Biocon Ltd.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Abevmy, Bevacizumab biosimilar, KRABEVA
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Australia
06 Sep 2021
Breast cancer recurrent
Australia
06 Sep 2021
High grade glioma
Australia
06 Sep 2021
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Australia
06 Sep 2021
Platinum-Resistant Epithelial Ovarian Carcinoma
Australia
06 Sep 2021
Platinum-Resistant Fallopian Tube Carcinoma
Australia
06 Sep 2021
Platinum-Resistant Primary Peritoneal Carcinoma
Australia
06 Sep 2021
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Australia
06 Sep 2021
Uterine Cervical Cancer
Australia
06 Sep 2021
Advanced Renal Cell Carcinoma
European Union
21 Apr 2021
Advanced Renal Cell Carcinoma
Iceland
21 Apr 2021
Advanced Renal Cell Carcinoma
Liechtenstein
21 Apr 2021
Advanced Renal Cell Carcinoma
Norway
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
European Union
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
Iceland
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
Liechtenstein
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
Norway
21 Apr 2021
Metastatic breast cancer
European Union
21 Apr 2021
Metastatic breast cancer
Iceland
21 Apr 2021
Metastatic breast cancer
Liechtenstein
21 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 3
Belarus
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Bosnia and Herzegovina
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Bulgaria
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Croatia
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Georgia
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Hungary
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
India
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Italy
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Philippines
21 Jan 2017
metastatic non-small cell lung cancerPhase 3
Poland
21 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
671
skxhaixkgk: Risk Ratio (RR) = 0.96 (90% CI, 0.83 - 1.12)
-
01 Feb 2021
Phase 3
671
gqcytvbfwm(ymmnitwzzo): ratio = 0.96 (90% CI, 0.73 - 1.36); difference = -1.6 (95% CI, -9.0 to 5.9)
Positive
17 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free